Advertisements
Feeds:
Posts
Comments

Archive for the ‘Curation’ Category


@ PharmaceuticalIntelligence.com –  A Case Study on the LEADER in Curation of Scientific Findings

Author: Aviva Lev-Ari, PhD, RN

 

Multi-facets of the LPBI Group Intellectual Property (IP) ASSETS

 

 

 

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

 

Innovations in e-Scientific Publishing Methodology Development accomplished by LPBI Group:

A.  Methodology for Curation of Scientific Findings – implementations for

  • Multi-Auhtors Authoring Cloud-based Platform

 

  • Journal Statistics – Interdisciplinary Journal covers interfaces of six domains (Life sciences, Pharmaceuticals, Medicine, Healthcare Policy, Biotech Intelligence and Medical Devices)

Curations of Scientific Findings of peer reviewed articles in top three journals in each of the Six domain

Curations written on a multi-Authoring platform by MDs, MD/PhDs, PharmD and PhDs, all 15 years after graduation of the advanced degree program, and each has a publication list before joined my team – they write clinical and medical interpretations of the scientific frontier as evidenced in the Scientific Finding section of published articles in Cell, Nature, Science, NEJM, other top journals in these six domains.

  1. Volume: 1.3 Million eReaders, ~5,150 Scientific articles, +500 categories of Research defining the Journal Ontology, 9,500 tags, 7,300, scientific comment on the articles submitted and exchange recorded between the Scientific community and our Team members
  2. Top two articles >25,000 eReaders
  3. Clicks on two Top Authors: >551,000
  4. from NIH +3,700 hits
  5. 2250 Journal subscribers by e-mail
  6. +6,200 Biotech Executive following up on LinkedIn
  • BioMed e-Series of e-Books in Medicine – 16 Volumes in Five e-Series: Cardiovascular, Genomics, Cancer, Immunology, Patient-centered Medicine

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

  • Team expertise
  1. e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
  2. FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 4/27/2017
  3. Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

B.  Methodology for REAL TIME Coverage of Scientific Conferences using Social Media and Real Time e-Proceedings Generation: Conferences in Biotech, Life Sciences and Medicine

  • In House Developed Methodology for Real Time Press Coverage of Biotech Top International conferences – selective  topics covered at conferences lead to NEW Curations in the Journal

https://pharmaceuticalintelligence.com/press-coverage/

 

9 results for Kindle Store : “Aviva Lev-Ari”

Sort by 
Relevance
Featured
Price: Low to High
Price: High to Low
Avg. Customer Review
Publication Date
Showing most relevant results. See all results for .
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Tilda Barliya PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Marcus W Feldman PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
Advertisements

Read Full Post »


Three Genres in e-Scientific Publishing AND Three Scientists’ Dilemmas

Curator: Aviva Lev-Ari, PhD, RN

 

That’s what I tell students. The way to succeed is to get born at the right time and in the right place. If you can do that then you are bound to succeed. You have to be receptive and have some talent as well.

Professor Sydney Brenner, a professor of Genetic medicine at the University of Cambridge and Nobel Laureate in Physiology or Medicine in 2002

 

 

Cell/Nature/Science

[CNS]

 Subscription-based Access

Open Access

  1. Online journals, to which scientists pay an upfront free to cover editing costs, which then ensure the work is available free to access for anyone in perpetuity

 

Curation of Scientific Findings

i.e., Kindle Direct Publishing [KDP] – Royalty-based system

  1. Free content to e-Readers
  2. Expert, Authors, Writers -Volunteers
  3. Editor -Voluneers
Confirming or disproving past studies Confirming or disproving past studies
Decades-long pursuit of a risky “moonshot” Decades-long pursuit of a risky “moonshot”
Trendy topics with Editors Trendy topics with Editors

 

Genres in e-Scientific Publishing

(A) Cell/Nature/Science

 – June 27, 2017

Elizabeth Dzeng — Feb 24th, 2014

  • http://www.cell.com/
  • http://www.sciencemag.org/
  • https://www.nature.com/
  • In 1998, Elsevier rolled out its plan for the internet age, which would come to be called “The Big Deal”. It offered electronic access to bundles of hundreds of journals at a time: a university would pay a set fee each year – according to a report based on freedom of information requests, Cornell University’s 2009 tab was just short of $2m – and any student or professor could download any journal they wanted through Elsevier’s website. Universities signed up en masse. …. Elsevier owned 24% of the scientific journal market, while Maxwell’s old partners Springer, and his crosstown rivals Wiley-Blackwell, controlled about another 12% each. These three companies accounted for half the market. (An Elsevier representative familiar with the report told me that by their own estimate they publish only 16% of the scientific literature.)  – June 27, 2017.  Elsevier published 420,000 papers last year, after receiving 1.5m submissions  – June 28, 2017 [numbers correction to 6/27/2017.]

(B) Open Access Journals and the Phenomenon

  1. Biochemistry
  2. Biophysics and Structural Biology
  3. Cancer Biology
  4. Cell Biology
  5. Computational and Systems Biology
  6. Developmental Biology and Stem Cells
  7. Epidemiology and Global Health
  8. Genomics and Evolutionary Biology
  9. Microbiology and Infectious Disease
  10. Neuroscience

(C) Curation of Scientific Findings

Scientists’ Dilemmas

(1) Confirming or disproving past studies

(2) Decades-long pursuit of a risky “moonshot”

(3) Trendy Topics with Editors 

 

@ PharmaceuticalIntelligence.com –  A Case Study on the LEADER in Curation of Scientific Findings

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

Product Details

Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

Nov 29, 2015 | Kindle eBook

by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
Subscribers read for free.
Auto-delivered wirelessly
Sold by: Amazon Digital Services LLC

 

Read Full Post »


e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Author and Editor-in-Chief: Aviva Lev-Ari, PhD RN

 

In this article I cover the Business Synopsis and the following Four Parts of the Business:

Part 1: The Vision

Part 2: Scientific Journal – Site Statistics on 6/20/2017

Part 3: BioMed e-Series

Part 4: Real Time Coverage of 50 Biotech Top Conferences

 

 

Synopsis

  • Interdisciplinary Journal covers interfaces of six domains

(Life sciences, Pharmaceuticals, Medicine, Healthcare Policy, Biotech Intelligence and Medical Devices)

  • Curations of Scientific Findings of peer reviewed articles in top three journals in each of the Six domain
  • Curations written on a multi-Authoring platform by MDs, MD/PhDs, PharmD and PhDs, all 15 years after graduation of the advanced degree program, and each has a publication list before joined my team – they write clinical and medical interpretations of the scientific frontier as evidenced in the Scientific Finding section of published articles in Cell, Nature, Science, NEJM, other top journals in these six domains.
  • Volume, ~5,150 Scientific articles, +500 categories of Research defining the Journal Ontology, 9,500 tags, 7,300, scientific comment on the articles submitted and exchange recorded between the Scientific community and our Team members
  • Top two articles >25,000 eReaders
  • Clicks on two Top Authors: >551,000
  • from NIH +3,700 hits
  • 2250 Journal subscribers by e-mail
  • +6,200 Biotech Executive following up on LinkedIn
  • BioMed e-Series: 16 volumes, 9 on Amazon.com

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

  • In House Developed Methodology for Real Time Press Coverage of Biotech Top International conferences – selective  topics covered at conferences lead to NEW Curations in the Journal

 

Part 1: The Vision

https://pharmaceuticalintelligence.com/vision/

Part 2: Scientific Journal – Site Statistics on 6/20/2017

https://pharmaceuticalintelligence.com/

1.3 Million eReaders on WordPress.com in 6/2017

Best ever daily views

2,508 views

Our DOMAINS in Scientific Media

I.  Pharmaceutical: Biologics, Small Molecules, Diagnostics

II.  Life Sciences: Genomics and Cancer Biology

III.  Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology

IV. Biomedicine, BioTech, and MedTech (Medical Devices)

V.  HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

 

All time

1,236,276 eReaders & 1,239,246 on 6/25/2017

2,243 Subscribers by e-mail

7,270 Scientific comments

5,126 Scientific Articles

561 Categories of Research – Journal Ontology

9,591 Tags

Followers (includes Publicize)

790 Twitter

699 Facebook

67 Tumblr

Top Posts >3,000 Views for all days ending 2017-06-20 (Summarized)

Clicks for all days ending 2017-06-20 (Summarized)

Referrers All Time >1,000 from one Source

Referrer Views
Search Engines   641,404
linkedin.com   24,641
Facebook 7,042
lnkd.in 6,285
scholar.google.com 3,747
Twitter 3,134
android-app 1,100
investorshub.advfn.com 1,062

Content

Top Authors for all days ending 2017-06-20 (Summarized)

Our Team Authors Author Views
Aviva Lev-Ari, PhD RN 322,313
Larry H Bernstein, MD, FCAP 226,768
Tilda Barliya, PhD 48,229
Stephen J Williams, PhD 40,966
Dror Nir, PhD 24,975
Sudipta Saha, PhD 22,713
Ritu Saxena, PhD 15,448
Demet Sag, Ph.D., CRA, GCP 13,315
Aviral Vatsa, PhD 8,132
Ziv Raviv, PhD 7,649
zs22 3,874
Gail S Thornton, MA, PhD(c) 3,535
Anamika Sarkar, PhD 3,280
Danut Dragoi, PhD 2,746
Prabodh Kandala, PhD 2,118
Alan F. Kaul, PharmD., MS, MBA, FCCP 2,065
Aashir Awan, PhD 1,865
Justin D Pearlman, MD, PhD, FACC 1,467
Meg Baker, PhD 1,447
Irina Robu, PhD 969
S. Chakrabarti, Ph.D. 641
Ed Kislauskis, PhD 585
Howard Donohue, PhD 537
David Orchard-Webb, PhD 465
Evelina Cohn, PhD 371
Stuart Cantor, PhD 368
Marzan Khan, BSc – Research Associate 355
apreconasia, DVM 342
Jukka Karjalainen, MD, PhD 229
anayou1, PhD 224
Sreedhar Tirunagari, PhD 158
gerag2015, ESQ 112
Larry Mulligan , PhD 91
Kelly Perlman, BSc (c) Research Associate 66
Rosalind Codrington, PhD 32

Graphics for 4/2012 to 3/10/2015

Part 3: BioMed e-Series

  • The Methodology of Co-Curation


Image Source: Original Graphic Conceptualization of the Co-Curation Concept by Stephen J Williams, 3/10/2015

Titles in the BioMed e-Series: 16 e-Books in Medicine and Life Sciences

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

9 results for Kindle Store : “Aviva Lev-Ari”

  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC

Forthcoming e-Books in 2017 & 2018

https://pharmaceuticalintelligence.com/biomed-e-books/

 

 

Analytics for the BioMed e-Series based on:

  1. Number of Articles per Volume
  2. E-Readers per Article
  3. Volume e-Impression since DATE of Publication [Summation of 2, above for all articles inside each Volume, before it was inside an e-Book and after the DATE of publication [Product details per Volume in attachment – Five e-Series – several Volumes per e-Series]

PENDING

 

Part 4: Real Time Coverage of 50 Biotech Top Conferences

https://pharmaceuticalintelligence.com/press-coverage/

 

Other related articles to e-Scientific Publishing include the following: 

 

 

 

Read Full Post »


Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Editor-in-Chief http://pharmaceuticalintelligence.comAviva Lev-Ari, PhD, RN

We have identified the following FIVE Innovations and provide Case Studies to demonstrate these statements.

Innovation #1:

Methodology of Expert Curation of Scientific Findings is applied in all the articles that are included in LPBI Group’s 16 e-Books

Innovation #2:

The Journal Archive by Month is sorted by Categories of Research that can serve multiple Goals in eScientific Publishing

Innovation #3:

Marketing of electronic Scientific Contents – eReaders’ Views Analytics: Site Statistics, Top Article Views, Top Author’s Views

Innovation #4:

Cross section of several Categories of Research supports interdisciplinary conceptual innovations – it is evidence that knowledge is in SILOS to a great degree, still.

Innovation #5:

Real Time Press coverage of Scientific Conferences Builds exposure to FRONTIER of Science that guides CONTENT creation in the Journal and in the BioMed e-Series

 

Case Studies for Innovations #1, #2, #3, #4, #5

 

Innovation #1:

1.1  Methodology of Expert Curation of Scientific Findings is applied in all the articles that are included in LPBI Group’s 16 e-Books

Editorial & Publication of Articles in e-Books by  Leaders in Pharmaceutical Business Intelligence:  Contributions of Larry H Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence:  Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/founder/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence/

1.2  The Methodology of Expert Curation of Scientific Findings deserves the status of an eScientific Publishing Class, in its own right – Our 5100 articles demonstrate that capability and virtue

http://pharmaceuticalintelligence.com

  • Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

Innovation #2:

The Journal Archive by Month is sorted by Categories of Research that can serve multiple Goals in eScientific Publishing:

 

2.1  Repository for generation of electronic Table of Contents (eTOCs) used in creation of electronic Books (eBooks).

Examples include our BioMed e-Series:

Forthcoming SEVEN e-Books in 2017/18 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

BioMed e-Series

https://pharmaceuticalintelligence.com/biomed-e-books/

BioMed e-Series

WE ARE ON AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_ss_i_1_15?url=search-alias%3Dstripbooks&field-keywords=aviva+lev-ari+phd+rn&sprefix=%22Aviva+Lev-Ari%2C%2Caps%2C129&crid=3V1F20IV5LHE3

2.2  Categories of Research serves as Ontologies for Journals

Examples. include our Open Access Online Scientific Journal

http://pharmaceuticalintelligence.com

Our DOMAINS in Scientific Media

I.  Pharmaceutical: Biologics, Small Molecules, Diagnostics

II.  Life Sciences: Genomics and Cancer Biology

III.  Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology

IV. Biomedicine, BioTech, and MedTech (Medical Devices)

V.  HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

Innovation #3:

Marketing of electronic Scientific Contents – eReaders’ Views Analytics: Site Statistics, Top Article Views, Top Author’s Views

 

3.1 Site Statistics on 5/5/52017

1,208,981 Views – all articles [not only articles with e-Views >1,000 = 445,321]

7,267 Scientific Comments

5,096 articles

9,566 tags

578 Categories of Research

3.2 FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by

e-Views >1,000, 4/27/2012 to 4/27/2017

Article Title

 

Views All Time

Author

Home page / Archives

445,321

e-Readers

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

15,461

Larry H. Bernstein, MD, FCAP

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

10,005

 

Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

3.3  Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com 

4/30/2012 – 4/25/2017 (All Times – Summarized)

Author

Views

Aviva Lev-Ari, PhD, RN

315,262

 

Larry H Bernnstein, MD, FCAP

220,787

Tilda Barliya, PhD

47,008

 

Stephen J Williams, PhD

39,704

Dror Nir, PhD

24,484

Sudipta Saha, PhD

22,253

Ritu Saxena, PhD

15,302

Demet Sag, Ph.D., CRA, GCP

12,982

Aviral Vatsa, PhD

8,082

Ziv Raviv, PhD

7,525

Zohi Sternberg, PhD

3,839

Anamika Sarkar, PhD, MBA

3,269

Gail S Thornton, MA, PhD(c)

2,885

Danut Dragoi, PhD

2,607

Prabodh Kandala, PhD

2,115

Alan F. Kaul, PharmD., MS, MBA, FCCP

2,057

Aashir Awan, PhD

1,841

Meg Baker, PhD

1,439

Justin D Pearlman, MD, PhD

1,429

https://pharmaceuticalintelligence.com/2017/04/25/top-authors-by-5-years-of-e-views-4252017-on-pharmaceuticalintelligence-com/

Innovation #4:

Cross section of several Categories of Research supports interdisciplinary conceptual innovations – it is evidence that knowledge is in SILOS to a great degree, still.

 

Examples for interdisciplinary conceptual innovations include:

  • Dr. Aviva Lev-Ari‘s early curations represent an intersection of Vascular Biology and Molecular Cardiology – that has yielded a Novel Combination Drug Therapy Concept in cardiovascular diseases.

Cardiovascular Diseases and Pharmacological Therapy: Curations

 

  • Dr. Larry H. Bernstein, MD, FCAP curations in Enzymology and Pathophysiology

ATP – the universal energy carrier in the living cell: Reflections on the discoveries and applications in Medicine

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics

Editor: Larry H. Bernstein, MD, FCAP

http://www.amazon.com/dp/B019VH97LU

Cyclic Dinucleotides and Histone deacetylase inhibitors

Curators: Larry H. Bernsten, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

  • Dr. Stephen J. Williams curations in Pharmacology and Oncology

Why Does Cytotoxic Chemotherapy Still Remain a Mainstay in Many Chemotherapy Regimens

New Generation of Platinated Compounds to Circumvent Resistance

New Topoisomerase Inhibitors: Agents From Nature

Are Cyclin D Inhibitors a Good Target?

 

  • Dr. Dror Nir’s curations in Medical Imaging and Oncology

Imaging Technology in Cancer Surgery

Metastatic Diseases – Examples of Surgical Procedures in Treatment of Cancer

Ablation Techniques in Interventional Oncology

 

  • Dr. Tilda Barliya’s curations in Nanotechnology, Molecular Biology and Drug Delivery

Building a Drug-Delivery System (DDS): choice of polymers and drugs

Factors affecting the PK of the nanocarrier

Detection and Imaging

Single-Molecule Detection by Philip Tinnefeld

Mesothelin: An early detection biomarker for cancer (By Jack Andraka)

Nanotechnology and MRI imaging

Nanotechnology: Detecting and Treating metastatic cancer in the lymph node

Diagnosing lung cancer in exhaled breath using gold nanoparticles

Innovation #5:

Real Time Press coverage of Scientific Conferences Builds exposure to FRONTIER of Science that guides CONTENTS creation in the Journal and in the BioMed e-Series

 

5.1 Press Coverage of BioTech, Medicine and Life Sciences Conferences, 2013 – 2017

https://pharmaceuticalintelligence.com/press-coverage/

List of Conferences in 2017

The 13th Annual Personalized Medicine Conference, NOVEMBER 14 – 16, 2017, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston

https://pharmaceuticalintelligence.com/2017/03/13/the-13th-annual-personalized-medicine-conference-from-concept-to-the-clinic-november-14-16-2017-joseph-b-martin-conference-center-harvard-medical-school-77-avenue-louis-pasteur-boston/

 

16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 2017, 9AM – 5PM, Kresge Auditorium, MIT

https://pharmaceuticalintelligence.com/2017/03/13/16th-annual-cancer-research-symposium-koch-institute-friday-june-16-9am-5pm-kresge-auditorium-mit/

 

BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-25, 2017, Seaport World Trade Center, Boston, MA

https://pharmaceuticalintelligence.com/2017/01/12/2017-agenda-bioinformatics-track-6-bioit-world-conference-expo-17-may-23-35-2017-seaport-world-trade-center-boston-ma/

 

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

https://pharmaceuticalintelligence.com/2016/12/14/2017-world-medical-innovation-forum-cardiovascular-may-1-3-2017-partners-healthcare-boston-at-the-westin-hotel-boston/

 

2017 MassBio Annual Meeting March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

https://pharmaceuticalintelligence.com/2017/02/28/2017-massbio-annual-meeting-march-30-2017-800-am-march-31-2017-400-pm-royal-sonesta-boston-cambridge-ma/

 

5.2  eProceedings generated in Real Time, Social Media facilitate Global e-Readers Reach and instantaneous reach of conference attendees 

  • World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(c)  Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

 

5.3 Opportunities for Import of Innovations from Conferences to the Journal and to the BioMed e-Series

From World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care

 

12. Aging and Heart Disease: Can we reverse the process?

11.Nanotechnologies for Cardiac Diagnosis and Treatment

10. Breaking the Code: Diagnosis and Therapeutic Potential of RNA

9. Expanding the Pool of Organs for Transplant

8. Finding Cancer therapies without Cardiotoxicity

7. Less is more: Minimalist Mitral Valve Repair

6. Understanding Why exercise works for Just about every thing

5. Power Play: The Future of Implantable Cardiac Devices

4. Adopting the Orphan of Heart Disease

3. Targeting Inflammation in cardiovascular Disease

2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

Read Full Post »


Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Babies born at or before 25 weeks have quite low survival outcomes, and in the US it is the leading cause of infant mortality and morbidity. Just a few weeks of extra ‘growing time’ can be the difference between severe health problems and a relatively healthy baby.

 

Researchers from The Children’s Hospital of Philadelphia (USA) Research Institute have shown it’s possible to nurture and protect a mammal in late stages of gestation inside an artificial womb; technology which could become a lifesaver for many premature human babies in just a few years.

 

The researchers took eight lambs between 105 to 120 days gestation (the physiological equivalent of 23 to 24 weeks in humans) and placed them inside the artificial womb. The artificial womb is a sealed and sterile bag filled with an electrolyte solution which acts like amniotic fluid in the uterus. The lamb’s own heart pumps the blood through the umbilical cord into a gas exchange machine outside the bag.

 

The artificial womb worked in this study and after just four weeks the lambs’ brains and lungs had matured like normal. They had also grown wool and could wiggle, open their eyes, and swallow. Although this study is looking incredibly promising but getting the research up to scratch for human babies still requires a big leap.

 

Nevertheless, if all goes well, the researchers hope to test the device on premature humans within three to five years. Potential therapeutic applications of this invention may include treatment of fetal growth retardation related to placental insufficiency or the salvage of preterm infants threatening to deliver after fetal intervention or fetal surgery.

 

The technology may also provide the opportunity to deliver infants affected by congenital malformations of the heart, lung and diaphragm for early correction or therapy before the institution of gas ventilation. Numerous applications related to fetal pharmacologic, stem cell or gene therapy could be facilitated by removing the possibility for maternal exposure and enabling direct delivery of therapeutic agents to the isolated fetus.

 

References:

 

https://www.nature.com/articles/ncomms15112

 

 

https://www.sciencealert.com/researchers-have-successfully-grown-premature-lambs-in-an-artificial-womb

 

http://www.npr.org/sections/health-shots/2017/04/25/525044286/scientists-create-artificial-womb-that-could-help-prematurely-born-babies

 

http://www.telegraph.co.uk/science/2017/04/25/artificial-womb-promises-boost-survival-premature-babies/

 

https://www.theguardian.com/science/2017/apr/25/artificial-womb-for-premature-babies-successful-in-animal-trials-biobag

 

http://www.theblaze.com/news/2017/04/25/new-artificial-womb-technology-could-keep-babies-born-prematurely-alive-and-healthy/

 

http://www.theverge.com/2017/4/25/15421734/artificial-womb-fetus-biobag-uterus-lamb-sheep-birth-premie-preterm-infant

 

http://www.abc.net.au/news/2017-04-26/artificial-womb-could-one-day-keep-premature-babies-alive/8472960

 

https://www.theatlantic.com/health/archive/2017/04/preemies-floating-in-fluid-filled-bags/524181/

 

http://www.independent.co.uk/news/health/artificial-womb-save-premature-babies-lives-scientists-create-childrens-hospital-philadelphia-nature-a7701546.html

 

https://www.cnet.com/news/artificial-womb-births-premature-lambs-human-infants/

 

https://science.slashdot.org/story/17/04/25/2035243/an-artificial-womb-successfully-grew-baby-sheep—-and-humans-could-be-next

 

http://newatlas.com/artificial-womb-premature-babies/49207/

 

https://www.geneticliteracyproject.org/2015/06/12/artificial-wombs-the-coming-era-of-motherless-births/

 

http://news.nationalgeographic.com/2017/04/artificial-womb-lambs-premature-babies-health-science/

 

https://motherboard.vice.com/en_us/article/artificial-womb-free-births-just-got-a-lot-more-real-cambridge-embryo-reproduction

 

http://www.disclose.tv/news/The_Artificial_Womb_Is_Born_Welcome_To_The_WORLD_Of_The_MATRIX/114199

 

 

Read Full Post »


Previously undiscerned value of hs-troponin

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

LPBI

 

Troponin Rise Predicts CHD, HF, Mortality in Healthy People: ARIC Analysis

Veronica Hackethal, MD

Increases in levels of cardiac troponin T by high-sensitivity assay (hs-cTnT) over time are associated with later risk of death, coronary heart disease (CHD), and especially heart failure in apparently healthy middle-aged people, according to a report published June 8, 2016 in JAMA Cardiology[1].

The novel findings, based on a cohort of >8000 participants from the Atherosclerosis Risk in Communities (ARIC) study followed up to 16 years, are the first to show “an association between temporal hs-cTnT change and incident CHD events” in asymptomatic middle-aged adults,” write the authors, led by Dr John W McEvoy (Johns Hopkins University School of Medicine, Baltimore, MD).

Individuals with the greatest troponin increases over time had the highest risk for poor cardiac outcomes. The strongest association was for risk of heart failure, which reached almost 800% for those with the sharpest hs-cTnT rises.

Intriguingly, those in whom troponin levels fell at least 50% had a reduced mortality risk and may have had a slightly decreased risk of later HF or CHD.

“Serial testing over time with high-sensitivity cardiac troponins provided additional prognostic information over and above the usual clinical risk factors, [natriuretic peptide] levels, and a single troponin measurement. Two measurements appear better than one when it comes to informing risk for future coronary heart disease, heart failure, and death,” McEvoy told heartwire from Medscape.

He cautioned, though, that the conclusion is based on observational data and would need to be confirmed in clinical trials. Moreover, high-sensitivity cardiac troponin assays are widely used in Europe but are not approved in the US.

An important next step after this study, according to an accompanying editorial from Dr James Januzzi (Massachusetts General Hospital, Boston, MA), would be to evaluate whether the combination of hs-troponin and natriuretic peptides improves predictive value in this population[2].

“To the extent prevention is ultimately the holy grail for defeating the global pandemic of CHD, stroke, and HF, the main reason to do a biomarker study such as this would be to set the stage for a biomarker-guided strategy to improve the medical care for those patients at highest risk, as has been recently done with [natriuretic peptides],” he wrote.

The ARIC prospective cohort study entered and followed 8838 participants (mean age 56, 59% female, 21.4% black) in North Carolina, Mississippi, Minneapolis, and Maryland from January 1990 to December 2011. At baseline, participants had no clinical signs of CHD or heart failure.

Levels of hs-cTnT, obtained 6 years apart, were categorized as undetectable (<0.005 ng/mL), detectable (≥0.005 ng/mL to <0.014 ng/mL), and elevated (>0.014 ng/mL).

Troponin increases from <0.005 ng/mL to 0.005 ng/mL or higher independently predicted development of CHD (HR 1.41; 95% CI 1.16–1.63), HF (HR 1.96; 95% CI 1.62–2.37), and death (HR 1.50; 95% CI 1.31–1.72), compared with undetectable levels at both measurements.

Hazard ratios were adjusted for age, sex, race, body-mass index, C-reactive protein, smoking status, alcohol-intake history, systolic blood pressure, current antihypertensive therapy, diabetes, serum lipid and cholesterol levels, lipid-modifying therapy, estimated glomerular filtration rate, and left ventricular hypertrophy.

Subjects with >50% increase in hs-cTnT had a significantly increased risk of CHD (HR 1.28; 95% CI 1.09–1.52), HF (HR 1.60; 95% CI 1.35–1.91), and death (HR 1.39; 95% CI 1.22–1.59).

Risks for those end points fell somewhat for those with a >50% decrease in hs-cTnT (CHD: HR 0.47; 95% CI 0.22–1.03; HF: HR 0.49 95% CI 0.23–1.01; death: HR 0.57 95% CI 0.33–0.99).

Among participants with an adjudicated HF hospitalization, the group writes, associations of hs-cTnT changes with outcomes were of similar magnitude for those with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).

Few biomarkers have been linked to increased risk for HFpEF, and few effective therapies exist for it. That may be due to problems identifying and enrolling patients with HFpEF in clinical trials, Dr McEvoy pointed out.

“We think the increased troponin over time reflects progressive myocardial injury or progressive myocardial damage,” Dr McEvoy said. “This is a window into future risk, particularly with respect to heart failure but other outcomes as well. It may suggest high-sensitivity troponins as a marker of myocardial health and help guide interventions targeting the myocardium.”

Moreover, he said, “We think that high-sensitivity troponin may also be a useful biomarker along with [natriuretic peptides] for emerging trials of HFpEF therapy.”

But whether hs-troponin has the potential for use as a screening tool is a question for future studies, according to McEvoy.

In his editorial, Januzzi pointed out several implications of the study, including the possibility for lowering cardiac risk in those with measurable hs-troponin, and that HF may be the most obvious outcome to target. Also, optimizing treatment and using cardioprotective therapies may reduce risk linked to increases in hs-troponin. Finally, long-term, large clinical trials on this issue will require a multidisciplinary team effort from various sectors.

“What is needed now are efforts toward developing strategies to upwardly bend the survival curves of those with a biomarker signature of risk, leveraging the knowledge gained from studies such as the report by McEvoy et al to improve public health,” he concluded.

 

Read Full Post »


Toxicities Associated with Immuno-oncology Treatment

Larry H. Bernstein, MD, FCAP

Curator: LPBI

 

ICLIO: Be Aware of Novel Toxicities With New Ca Drugs  

Advent of new immunotherapies warrants education for non-oncologists

by Eric T. Rosenthal
Special Correspondent, MedPage Today
http://www.medpagetoday.com/HematologyOncology/Chemotherapy/58582

CHICAGO — A new class of cancer immunotherapies, led by pembrolizumab (Keytruda), has taken the oncology world by storm. But with this novel type of treatment comes a new challenge.

The Association of Community Cancer Centers (ACCC) wants to ensure that non-oncologist physicians know how to take care of their patients receiving these agents since doctors in other specialties may not be aware of the side effects related to the immunotherapies.

The initiative is one of the steps taken by the association’s Institute of Clinical Immuno-Oncology’s (ICLIO) in making immunotherapy available in the community.

ICLIO was launched 1 year ago to help prepare community cancer teams and centers to deal with the clinical, coverage, and reimbursement issues related to immunotherapy.

During the American Society of Clinical Oncology annual meeting here MedPage Todayspoke with ACCC President Jennie R. Crews, MD, and ICLIO Chair Lee S. Schwartzberg, MD, about the institute’s growth and future plans.

Schwartzberg, chief of the division of hematology and oncology at the University of Tennessee, as well as executive director of the West Cancer Center in Memphis, said that the field of immunotherapy “is moving so fast that we can’t have enough education.”

“Needs change over time and last year many cancer practices became familiar with immuno-oncology and now we have to go deeper and broader.”

The broadening, he explained, involves educating other medical subspecialists about immune-related toxicities from the new agents.

“The problem is that we see related toxicities that are not managed well, and we’re having trouble with this.”

He cited as two primary examples toxic side effects such as colitis and pneumonitis and the necessity of educating gastroenterologists and pulmonologists about their relationship to immunotherapy.

Many times these subspecialists, as well as dermatologists, endocrinologists, emergency physicians, and internists see autoimmune-related toxicities and first think they are from chemotherapy or infection, according to Schwartzberg.

“But they are going to be going down a very bad path with these patients if they think this way,” noting that a colleague from a leading cancer center had recently mentioned that the institution’s emergency room staff didn’t always understand about immunotherapy reactions.

He said that, although ICLIO does not have direct access to reaching many other subspecialists, it was beginning to develop educational materials that oncologists could share with other medical colleagues, as well as to work with some of the subspecialty societies.

“Education, however, has to be across the board, and has to include patients as well,” he said, adding that many cancer immunotherapy patients were being provided with cards that explained their immunotherapy and could be handed to nurses and physicians at the outset of their medical intervention, saving time and the risk of undergoing the wrong treatment.

In a separate interview, Crews, medical director for Cancer Services PeaceHealth at St. Joseph Medical Center in Bellingham, Wash., said that ACCC members include both academic centers and community practices including both hospital-based and private. (An ACCC public relations representative monitored the interview.)

“We are not focused on what the science is, but rather on how do we take this technology out to the community to bring cancer to where patients are,” she said, adding that she and others are very passionate in the belief that cancer care should be delivered wherever cancer patients live.

She said since ICLIO started in June 2015, much of its infrastructure and programs have been established, including a webinar series, eNewsletters, eLearning Modules, tumor subcommittee working groups, an on-site preceptorship program, an ICLIO stakeholder summit, and an upcoming second national conference this fall in Philadelphia.

That conference will be preceded by a stakeholder summit bringing together providers, patient advocates, payers, pharmaceutical producers, and others, which the ACCC hopes will produce a white paper.

The last year has seen the growth of the initiative’s Scholars Program to about 50 oncologists who have received training through ICLIO’s learning modules.

These scholars will in turn eventually be able to serve as mentors to the 2,000 cancer programs with some 20,000 individual members that make up ACCC’s membership.

Crews said that to date about 700 cancer programs involving some 1,900 individuals have participated in the webinars, and about 100 people attended ICLIO’s first annual conference last October.

She said that in addition to the charitable contribution initially made by Bristol-Myers Squibb last year to help launch ICLIO, Merck has also provided an educational grant, but she would not disclose the amount of the funding.

Read Full Post »

Older Posts »